Willow offers a comprehensive platform with integrated tools
The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status
People using tirzepatide , retatrutide , or other peptide injections face the same anatomical considerations
Lysine acetylation neutralizes the positive charge and increases the hydrophobicity of the lysine side chain
Talk to a Provider Medication may be considered based on clinical evaluation
Based on these mouse and human genetic associations, GIPR antagonism has been explored as a therapy to treat obesity (68)